Second, initial data have demonstrated that blocking HMGB1 is effective in ameliorating psoriasis similar to blocking some other alarmins (e.g., IL-33) in other chronic inflammatory skin diseases (e.g., atopic dermatitis). Here, IL33 is linked to atopic eczema.